Patents Assigned to Astellas Pharma Inc.
  • Publication number: 20210163533
    Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
    Type: Application
    Filed: December 10, 2018
    Publication date: June 3, 2021
    Applicants: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki Endo, Yukihito ISHIZAKA, Akira ISHIGURO, Tomoki TAKASHINA, Takashi YAMAMOTO, Tetsushi SAKUMA
  • Publication number: 20210147529
    Abstract: A novel pharmaceutical composition for suppressing atrial fibrillation that has an action mechanism that does not affect the normal heart function is provided. A pharmaceutical composition including an anti-human NGF antibody or antigen binding fragment thereof as an active ingredient is provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: May 20, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Kohsuke SHAKUSHIRO, Toshiaki AOKI
  • Patent number: 10994011
    Abstract: Provided is a stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants, or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 4, 2021
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Megumi Ikeda, Akinori Chikushi
  • Publication number: 20210113529
    Abstract: Provided is a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability. The inventors of the present invention have made investigations on a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, and have confirmed that a selective S1P receptor agonist having agonist activity at an S1P1 receptor has an intraocular neovascularization-reducing action and an intraocular vascular permeability-reducing action, thus completing the present invention.
    Type: Application
    Filed: February 1, 2019
    Publication date: April 22, 2021
    Applicants: KYOTO UNIVERSITY, Astellas Pharma Inc.
    Inventors: Hideaki HARA, Shuh NARUMIYA, Tomohiro AOKI, Ichiro ARAMORI, Rie YAMAMOTO
  • Patent number: 10975091
    Abstract: The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: April 13, 2021
    Assignees: Astellas Pharma Inc., KOTOBUKI PHARMACEUTICAL CO., LTD.
    Inventors: Kenichi Kawaguchi, Akihiro Ishihata, Yusuke Inagaki, Kazuyuki Tsuchiya, Tadaatsu Hanadate, Akira Kanai, Hiroyuki Kaizawa, Junichi Kazami, Hiroshi Morikawa, Masashi Hiramoto, Kentaro Enjo, Hajime Takamatsu
  • Patent number: 10946069
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 16, 2021
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Patent number: 10927413
    Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: February 23, 2021
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNTVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSIT MAINZ GGMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
  • Patent number: 10927185
    Abstract: [Problem] Provided is a bispecific antibody with a novel format that retains high binding affinity to both antigens, and can be efficiently produced in a commercial production process.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: February 23, 2021
    Assignee: Astellas Pharma Inc.
    Inventors: Yasuhiro Ito, Atsuo Yonezawa
  • Patent number: 10888594
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 12, 2021
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Publication number: 20200407692
    Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The disclosed method may include, for example, the steps of: (i) culturing the pluripotent stem cells under conditions that induce differentiation into renal progenitor cells; and (ii) sorting a cell population from the cells obtained at step (i), by using at least one cell surface marker selected from the group consisting of CD9(?), CD55(?), CD106(+), CD140a(+), CD140b(+), CD165(+), CD271(+) and CD326(?).
    Type: Application
    Filed: June 25, 2020
    Publication date: December 31, 2020
    Applicants: Astellas Pharma Inc., KYOTO UNIVERSITY
    Inventors: Tatsuya Kawamoto, Yukiko YAMAGISHI, Kenji OSAFUNE
  • Patent number: 10849946
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 1, 2020
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Patent number: 10842780
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 24, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako
  • Publication number: 20200360372
    Abstract: Provided are methods, uses, and compositions for treating acute myeloid leukemia which includes therapeutically effective combinations of 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide, or a salt thereof, and 4-amino-1-?-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, or a salt thereof.
    Type: Application
    Filed: July 30, 2020
    Publication date: November 19, 2020
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Erkut BAHCECI, Yoko YAMAKI
  • Publication number: 20200338149
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 29, 2020
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Shinsuke NAKAO, Tatsuya KAWASE, Takafumi NAKAMURA
  • Patent number: 10813996
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: October 27, 2020
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT AT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • Patent number: 10786500
    Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 29, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
  • Publication number: 20200299371
    Abstract: Provided is a stable pharmaceutical composition comprising a PEGylated Fab? fragment of an anti-human NGF antibody, capable of inhibiting the formation of degradation products, multimers, acidic related substances, basic related substances, and insoluble foreign substances. The pharmaceutical composition has a pH of 4 to 5.5, and can further comprise a pharmaceutically acceptable buffer, a pharmaceutically acceptable isotonizing agent, and a pharmaceutically acceptable surfactant, if desired.
    Type: Application
    Filed: March 24, 2017
    Publication date: September 24, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Ayano YAMAMOTO, Akinori CHIKUSHI
  • Publication number: 20200289592
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: April 30, 2020
    Publication date: September 17, 2020
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Takafumi Nakamura, Hajime KUROSAKI, Motomu NAKATAKE
  • Publication number: 20200289505
    Abstract: [Problem] A compound useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for cancer immunotherapy, and/or a pharmaceutical composition for immunological activation is provided. [Means for Solution] The present inventors have conducted intensive studies for the purpose of creating a pharmaceutical composition for cancer immunotherapy and/or a pharmaceutical composition for immunological activation.
    Type: Application
    Filed: April 28, 2020
    Publication date: September 17, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Tomohiro Eguchi, Taku Yoshida, Ruriko Kado
  • Patent number: 10774082
    Abstract: [Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: September 15, 2020
    Assignee: Astellas Pharma Inc.
    Inventors: Kazuyuki Kuramoto, Michinori Akaiwa, Tomoaki Abe, Takanobu Araki, Susumu Yamaki, Shigeki Kunikawa, Tomoyoshi Imaizumi, Takahiro Nigawara, Keisuke Arakawa, Itsuro Shimada, Masashi Shimazaki, Yoshiki Satake, Kazushi Watanabe, Takanori Koike